Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | August 31, 2023 | September 01, 2023 |
| PRF Technologies Ltd.PRFX · Entity 8440 | Director | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 31, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series Y Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 24.573 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
| Series Y Preferred StockSEC Table I · non-derivative | IndirectBy The Lawlor Family Trust UAD 4-17-00 | 0 |
Reported balance
After 2023-08-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-31 · Disposition to issuer · Disposed 24.215 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.
PRF Technologies Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5,400.00 · Expires 2031-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2034-07-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F3: The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2019 PainReform Option Plan.
F2: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.
F3: The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CYPHERPUNK TECHNOLOGIES INC.
Report date June 30, 2025 · Filed July 01, 2025
Section 16 reporting ended · disclosed 2025-07-01. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Cardiovascular Systems Inc
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 5,022 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy Lawlor Family Trust | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-04-27 · Disposition to issuer · Disposed 25,318 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 103,719 · Balance 0 F2: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2019 Filed Feb 5, 2019 21:21 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | PurchaseCommon Stock | 571,428 | $1.75 | $999,999.00 |
DisclosureSEC source: 0001104659-19-005837 · a4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,114,804 F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:38 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001104659-19-000511 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-12-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of January 1, 2019, the Vesting Start Date. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001221 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,732 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 16:32 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 3,527 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000376 · edgar.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,527 Underlying: Common Stock · 3,527 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 882 shares on each of September 30, 2018, December 31, 2018 and March 31, 2019 and 881 shares on June 30, 2019. F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 882 shares on each of September 30, 2018, December 31, 2018 and March 31, 2019 and 881 shares on June 30, 2019. F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 882 shares on each of September 30, 2018, December 31, 2018 and March 31, 2019 and 881 shares on June 30, 2019. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 16:32 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 1,960 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000376 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,508 F1 · shares: Represents restricted stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a director of the Company during fiscal year 2019. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 23:21 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | OtherWarrant (Right to Buy) · Derivative | 21,369 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001104659-18-048861 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 21,369 Underlying: Common Stock · 21,369 shares Expires 2024-11-14 F1 · kind: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Mr. Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. F2 · kind: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock. F1 · ownership.direct: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Mr. Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. F2 · ownership.direct: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock. F1 · ownership.nature: Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Mr. Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. F2 · ownership.nature: The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038137 · doc4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2018. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:03 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001104659-18-025611 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, $0.001 par value per share · 50,000 shares Expires 2028-04-17 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date. F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 18:45 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | PurchaseWarrant (Right to Buy) · Derivative | 1,057,769 | Not disclosed Strike: $6.09 | Not disclosed |
DisclosureSEC source: 0001104659-17-069118 · a4.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,057,769 Underlying: Common Stock, $0.001 par value per share · 1,057,769 shares Expires 2024-11-14 F4 · price: The reported securities were included with the 1,057,759 shares of common stock purchased by HealthCare Ventures IX, L.P. for $6.085 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 18:45 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | PurchaseCommon Stock | 1,057,769 | $6.09 | $6,436,524.37 |
DisclosureSEC source: 0001104659-17-069118 · a4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,573,376 F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 16:40 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 4,029 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000229 · edgar.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 Underlying: Common Stock · 4,029 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,008 shares on September 30, 2017 and 1,007 shares on each of December 31, 2017, March 31, 2018 and June 30, 2018. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,008 shares on September 30, 2017 and 1,007 shares on each of December 31, 2017, March 31, 2018 and June 30, 2018. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,008 shares on September 30, 2017 and 1,007 shares on each of December 31, 2017, March 31, 2018 and June 30, 2018. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 16:40 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000229 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,548 F1 · shares: Represents shares of common stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a Committee Chair during fiscal year 2018. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 20:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-17-045214 · doc4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 15, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:31 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | OtherCommon Stock | 74,670 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000064 · edgar.xml · nonDerivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HealthCare Ventures VIII, L.P. Disclosed balance after: 0 F2 · shares: Represents the liquidating distribution from Healthcare Ventures VIII, L.P. F3 · ownership.nature: The Reporting Person is a managing director of HealthCare Partners VIII, LLC, the general Partner of HealthCare Partners VIII, L.P. ("HCPVIII"). HCPVIII is the general Partner of the entity owning the shares. The Reporting Person disclaims beneficial ownership of those securities in which he does not have a pecuniary interest and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:31 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 130 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000064 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,131 F1 · shares: Represents shares of common stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a Committee Chair during fiscal year 2017. Read SEC document |
| January 23, 2017 Filed Jan 23, 2017 23:13 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 330,303 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001104659-17-003609 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,303 Underlying: Common Stock, $0.001 par value per share · 330,303 shares Expires 2027-01-22 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and shall vest and become exercisable with respect to 33 1/3% of the Option Shares on the one-year anniversary of January 23, 2017, the Vesting Start Date (the "First Vesting Date"), after which it shall vest in a series of 24 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of the First Vesting Date. F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and shall vest and become exercisable with respect to 33 1/3% of the Option Shares on the one-year anniversary of January 23, 2017, the Vesting Start Date (the "First Vesting Date"), after which it shall vest in a series of 24 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of the First Vesting Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.